You can install our site as a web app on your iOS device by utilizing the Add to Home Screen feature in Safari. Please see this thread for more details on this.
Note: This feature may not be available in some browsers.
Soooooo.... anyone else still in Western Lithium, now known as Lithium Americas? (They even changed their stock symbol to LACDF.)
Finally it's showing some positive activity, and I'm finally in the green after a long period of doldrums. I regret investing in this company because even though they talk about Lithium their main business has been manufacturing nasty chemicals used in fracking. Now that the stock seems to be jumping, I'm wondering when to exit. Greed says, stock around a bit more. Practicality says, get the hell out while you can.
I say, let greed and practicality duke it out a little more
As well. Both an owner of NVDA stock and options. Good day for a good company. If they are a player in Model 3 and all other autonomous efforts, Katie bar the door. Autonomous driving is a fraction of their current revenue.Today's market is responding super-positively to Nvidia's only slightly better than consensus 1Q numbers. NVDA reported $1.3bn in sales and 33¢ EPS vs. consensus of $1.26bn and 32¢. At 11am AK time, the stock is up 14.4% at $40.70, finally having broken its previous all-time high of $37.40 way back in Oct. 2007.
Automotive sector still represents a small fraction of this gaming-specialized GPU manufacturer - but there is very strong growth there.
Very happy today!
As well. Both an owner of NVDA stock and options. Good day for a good company. If they are a player in Model 3 and all other autonomous efforts, Katie bar the door. Autonomous driving is a fraction of their current revenue.
Follow up to this post: What other tech stock to consider?
Novavax has continued to execute well, I won't bother to recap. I'd suggest those interested read the shareholder letter here: Computershare Viewer
I have followed this company for years. I recall when the percentage of shares owned by institutions was in the 50% range. Following shows general dates and % ownership over time.
8/15 67.87%
2/16 73.56
3/16 75.73
4/19/16 77.11
5/14/16 79.49
5/17/16 83.08%
I own shares in a company I have followed for a long time. It is not a traditional tech company in the way many think of tech, but I see some discussion of medical products so thought I would throw this one to the mix. FD: I own shares and would love to see this post help the share price move along...
Years ago during the bird flu scare, I think 2007, I happened upon this company as a novel vaccine maker. It had no products on the market and was subject to massive hype. I lost some money.
As time went on, it stayed on my radar, and with maturity I think I saw things in a different manner. I adapted my hyperkinetic trading, focused on future growth stocks I could understand. I did well with TSLA stock/options. I've traded in and out some on this company, now have a lot riding on it.
NOVAVAX: NVAX Novavax www.novavax.com
Traditional vaccines are made using live viruses, grown in eggs, the virus gets inactivated or knocked back, the body recognizes the virus, builds immunity. The newer vaccines for HPV are manufactured from virus like particles, not a live virus. NVAX has proven the ability to make novel vaccines in similar manner. They have ongoing studies for several products, the biggest of which is for respiratory syncytial virus (RSV), a virus that companies have been trying to tame for many years. The CEO of the company thinks the RSV vaccine could become the best selling vaccine ever (or some other grandiose statement). RSV affects many newborns, is a major cause of newborn hospitalizations, and also affects the elderly. Data thus far has been promising. NVAX also developed vaccine candidates for H7N9 and Ebola, generally within 3 months of getting genetic info on the virus. In 2 animal studies, the EBOLA candidate conferred immunity, all animals lived, all control animals died. They are also working on quadrivalent flu vaccines, and hope to pair this vaccine up with RSV. Two candidates have received fast track designation in the states. They are partnered up with Cadilla in India.
They recently did a secondary offering and expect to have money on hand for several years.
Price decline to 7.25 secondary offering is max risk in my opinion, current price flirting with 9.
Institutional ownership at an all time high >65% Novavax, Inc. (NVAX) Institutional Ownership & Holdings - NASDAQ.com (THat is more than TSLA)
9 days short interest.
I've done simple back of the napkin calculations for future value based upon RSV alone, future target 33-83. This target was pre dilution.
Near term target 17, again simple back of napkin.
I've watched a few other pharmas get irrational with P/Es. If this happens, price target >200.
Company leadership has built, grown, sold company before.
THey are engaging thought leaders in the industry to create RSV support.
They are hiring.
The executives have said many times over that the coming 2 quarters have lots of catalysts.
There is a new owner of 14M shares
Good luck.
Kuka Aktiengesellschaft (KUKAF, they make most of the robots for the production line) was up 13% today. Not entirely sure why; the US ADRs are thinly traded and there's almost no news. Maybe it was just pent up demand from the (presumed) acceleration of the TSLA production line.